Evening Primrose Oil for Hot Flashes: What the Evidence Shows

Evening primrose oil has cleared one narrow clinical hurdle for menopausal hot flashes: a 2026 meta-analysis found that episodes lasted less long. But the same analysis found no statistically significant reduction in how often hot flashes occurred or how intense they felt. For someone waking drenched at 3 a.m., that is a meaningful distinction.

The evidence does not show that evening primrose oil is useless. It shows that its case remains incomplete. The best available synthesis included only about 450 peri- and postmenopausal women across six randomized trials, and its overall certainty ratings ranged from moderate to low. A supplement can be "natural" and still need to earn its place in the medicine cabinet.

A duration benefit, without fewer or milder hot flashes

Larki et al.'s 2026 systematic review and meta-analysis pooled six randomized controlled trials that compared evening primrose oil with placebo or no treatment in peri- and postmenopausal women. Unlike an earlier review, it excluded studies of multi-herb products and combinations such as evening primrose oil plus black cohosh. That matters because a blend cannot tell us what evening primrose oil did on its own.

The pooled result was statistically significant for the duration of individual hot flashes. It was not statistically significant for hot-flash frequency or intensity. The publication's accessible text does not report the pooled mean difference, confidence interval, exact p value, or heterogeneity statistic for each outcome, so a precise effect size cannot be responsibly quoted.

Duration may matter to some people, particularly if episodes are prolonged. Still, frequency and intensity usually drive the daily burden: how many times symptoms interrupt work, sleep, exercise, or a conversation that was going perfectly well until the thermostat in your brain started freelancing. When neither endpoint improved significantly, an isolated duration result offers limited evidence of broad symptom relief.

Why the result is less settled than it sounds

A meta-analysis is only as convincing as the trials inside it. These six trials were small, and roughly 450 participants in total leaves limited power to detect modest effects. The null findings for frequency and intensity could mean evening primrose oil has little or no effect on those outcomes. They could also mean the studies were too small to detect a small benefit. Neither interpretation justifies a confident efficacy claim.

The review used the modern ROB2 risk-of-bias tool and GRADE framework, but its certainty ratings still ranged from moderate to low. Oil supplements also create an awkward blinding problem. If the active oil and placebo differ in taste, texture, or gastrointestinal effects, participants or study staff may guess the assignment. That can alter symptom reporting in either direction.

Most included trials took place in Iran, which narrows generalizability. Menopausal symptoms, diet, baseline intake of fatty acids, and supplement use can differ across populations. With fewer than 10 studies, the review also could not formally assess publication bias using common methods such as funnel plots or Egger's test. Small unpublished negative studies remain possible.

The proposed mechanism is plausible, but unproven

Evening primrose oil contains gamma-linolenic acid, or GLA. The proposed pathway runs from GLA to dihomo-gamma-linolenic acid and then prostaglandin E1, which may affect vascular or thermoregulatory signaling. That is a hypothesis, not a demonstrated explanation for shorter hot flashes in menopausal women.

Research on vasomotor symptoms points more directly toward hypothalamic neurokinin B signaling. A 2023 genome-wide analysis by Ruth and colleagues added genetic support for the neurokinin B/NK3 receptor pathway in menopausal vasomotor symptoms. Estrogen withdrawal is thought to increase neurokinin B activity, setting off the heat-dissipation response. Available evidence has not established a bridge between evening primrose oil's proposed prostaglandin pathway and this neurokinin B/NK3 receptor circuit.

That gap does not disprove the supplement. Biology often has side streets. It does mean that a tidy mechanism should not substitute for patient outcomes.

How evening primrose oil compares with established options

Menopause hormone therapy remains the treatment with the deepest evidence base for eligible women with troublesome vasomotor symptoms. French CNGOF/GEMVi clinical guidelines recommend individualized management and identify menopause hormone therapy as first-line treatment for women in early postmenopause, generally within 10 years of natural menopause, when appropriate for their risk profile.

For people who cannot use hormones or prefer not to, NK3 receptor antagonists have stronger evidence than evening primrose oil for the outcomes that most affect daily life. A 2025 systematic review and meta-analysis found that fezolinetant and elinzanetant outperformed placebo on vasomotor-symptom frequency and severity. A separate fezolinetant meta-analysis of 3,291 participants reported dose-dependent efficacy, a pooled sample more than seven times larger than the evening primrose oil evidence base.

Fezolinetant also has data beyond hot-flash counts. In pooled phase 3 SKYLIGHT 1 and 2 trials, 1,022 participants aged 40 to 65 with moderate-to-severe vasomotor symptoms were randomized to placebo, fezolinetant 30 mg, or fezolinetant 45 mg for 12 weeks. The pooled sleep analysis found significant improvements in patient-reported sleep disturbance and sleep-related impairment. Evening primrose oil trials have not supplied comparable evidence for vasomotor-symptom-related sleep outcomes.

Other approaches remain under study. A 12-week randomized dietary intervention in 84 postmenopausal women with at least two moderate-to-severe daily hot flashes tested a low-fat vegan diet plus 86 g of cooked soybeans daily against usual diet; participants recorded symptom frequency and severity in an app. The exploratory analysis reported reduced hot flashes with the intervention, while microbiome findings came from only 11 women and cannot establish a mechanism. A quasi-experimental yoga study also reported lower climacteric symptom scores over follow-up, but its design provides less protection from bias than a blinded randomized drug trial.

What to do with this information

Evening primrose oil is a possible personal experiment, not an evidence-based first choice for women seeking substantial relief from frequent or severe hot flashes. The best EPO-specific meta-analysis found a statistically significant reduction in episode duration, but not in frequency or intensity. The available trials are too small and too limited to close the question, yet they do not support treating the supplement as a substitute for therapies that improve both core outcomes.

Discuss bothersome symptoms with a clinician, especially if they affect sleep, work, mood, or quality of life. That conversation can cover whether hormone therapy fits your health history and which nonhormonal options are available. It should also cover supplement safety and possible drug interactions, because the EPO meta-analysis does not provide enough EPO-specific safety evidence to settle those questions.

The verdict: Evening primrose oil may shorten individual hot flashes, but current evidence does not show that it makes them happen less often or feel less severe. That is a modest finding, not herbal hormone therapy.